NeuroPace, Inc. announced preliminary financial results for Q4 and the year ended December 31, 2024, and appointed Scott Huennekens as a new director, with a stock option grant of 15,507 shares at $11.93 each.
AI Assistant
NEUROPACE INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.